Home › Duchenne Muscular Dystrophy › California
Duchenne Muscular Dystrophy clinical trials in California
6 studies for Duchenne Muscular Dystrophy are looking for participants at sites in California.
Cities in California
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
- Loma Linda University Pediatric Subspecialty Clinics, Loma Linda
- Children's Hospital Los Angeles, Los Angeles
- Valley Children's Hospital, Madera
- and 2 more
RecruitingObservational study
Ages 2 and older · Men · Updated Sep 24, 2026 · NCT06564974A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
- University of California, San Diego, La Jolla
- University of California, Los Angeles, Los Angeles
- Stanford University, Palo Alto
- and 1 more
RecruitingPhase 1
Ages 2 and older · Men · Updated Sep 11, 2026 · NCT04626674Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials
- UC Davis, Sacramento
RecruitingObservational study
All ages · All sexes · Updated Jul 28, 2026 · NCT07674758A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
- University of California, Los Angeles Medical Center, Los Angeles
- University of California, Davis, Sacramento
- University of California, San Diego
RecruitingPhase 1/2
Ages 0 to 17 · Men · Updated Jul 8, 2026 · NCT06138639Duchenne Electronic Health Record Study
- UC Davis Health, Sacramento
RecruitingObservational study
All ages · All sexes · Updated May 27, 2026 · NCT07609394Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
- Stanford University, Palo Alto
RecruitingObservational studyHealthy volunteers welcome
Ages 5 and older · All sexes · Updated Apr 9, 2026 · NCT06839469From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.